Description

Empagliflozin Tablets 10mg, branded as Koltangen, are classified as SGLT2 inhibitors, designed for research applications related to glucose excretion, renal glucose transport, and diabetic model development. These tablets assist researchers in studying the molecular pathways of sodium-glucose cotransport and its implications on blood glucose regulation.

Manufactured by Sichuan Kelun Pharmaceutical Co., Ltd., this formulation adheres to Chinese national medical standards under NMPA approval number H20203411.

?? For laboratory research use only. Not intended for clinical, diagnostic, or therapeutic applications.

Product Parameters

Mechanism & Research Applications

Empagliflozin acts as a selective SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor, which reduces glucose reabsorption in the kidneys, enhancing glucose excretion via urine.

Research applications include:

• Experimental studies on type 2 diabetes mellitus (T2DM)

• Investigations into renal glucose transport and glycosuria

• Research on cardiometabolic outcomes and kidney function

• Combination therapy models involving metformin or insulin

Observed Effects in Research

In non-clinical settings, Empagliflozin has demonstrated the following research observations:

• Enhanced urinary glucose excretion

• Reduced plasma glucose levels

• Mild diuretic effects

• Positive influence on body weight and blood pressure in animal models

• Cardiovascular protection markers in diabetic model animals

Safety & Handling

• Research Grade: Not for human or animal administration

• Handling: Use gloves and safety goggles

• Storage: Keep tightly sealed, dry, and at room temperature

• Shelf Life: Refer to product labeling

• Disposal: Follow chemical waste disposal protocols

Research Use Disclaimer

This product is intended solely for laboratory research purposes. It is not to be used in humans or animals. It must be handled only by qualified laboratory personnel under regulated environments.